StreetInsider.com News Articles

Harbour BioMed and BioMap Jointly Initiate MegaStream TechBio: A Leading Global Drug Development Platform Joins Forces with Premier Life Science Foundation Models to Set New Benchmarks for AI-Driven C

Mon, 15 Jun 2026 08:10:00 -0400

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 15, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142.HK), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, and BioMap, a global leader in AI foundation models for life sciences, today jointly announced a multi-dimensional, long-term strategic partnership centered on AI-driven discovery and development of complex biologics. The alliance aims to systematically overcome the critical bottlenecks constraining next-generation innovative therapies and to build a globally competitive, AI-powered R&D ecosystem.

Harbour BioMed and BioMap Jointly Initiate MegaStream TechBio: A Leading Global Drug Development Platform Joins Forces with Premier Life Science Foundation Models to Set New Benchmarks for AI-Driven C

Mon, 15 Jun 2026 08:10:00 -0400

Harbour BioMed and BioMap Jointly Initiate MegaStream TechBio: A Leading Global Drug Development Platform Joins Forces with Premier Life Science Foundation Models to Set New Benchmarks for AI-Driven C

Mon, 15 Jun 2026 08:10:00 -0400

Harbour BioMed and BioMap Jointly Initiate MegaStream TechBio: A Leading Global Drug Development Platform Joins Forces with Premier Life Science Foundation Models to Set New Benchmarks for AI-Driven C

Mon, 15 Jun 2026 08:10:00 -0400

Harbour BioMed and BioMap Jointly Initiate MegaStream TechBio: A Leading Global Drug Development Platform Joins Forces with Premier Life Science Foundation Models to Set New Benchmarks for AI-Driven C

Mon, 15 Jun 2026 08:10:00 -0400

Harbour BioMed and BioMap Jointly Initiate MegaStream TechBio: A Leading Global Drug Development Platform Joins Forces with Premier Life Science Foundation Models to Set New Benchmarks for AI-Driven C

Mon, 15 Jun 2026 08:10:00 -0400

Harbour BioMed and BioMap Jointly Initiate MegaStream TechBio: A Leading Global Drug Development Platform Joins Forces with Premier Life Science Foundation Models to Set New Benchmarks for AI-Driven C

Mon, 15 Jun 2026 08:10:00 -0400

Harbour BioMed and BioMap Jointly Initiate MegaStream TechBio: A Leading Global Drug Development Platform Joins Forces with Premier Life Science Foundation Models to Set New Benchmarks for AI-Driven C

Mon, 15 Jun 2026 08:10:00 -0400

Harbour BioMed and BioMap Jointly Initiate MegaStream TechBio: A Leading Global Drug Development Platform Joins Forces with Premier Life Science Foundation Models to Set New Benchmarks for AI-Driven C

Mon, 15 Jun 2026 08:10:00 -0400

Harbour BioMed and BioMap Jointly Initiate MegaStream TechBio: A Leading Global Drug Development Platform Joins Forces with Premier Life Science Foundation Models to Set New Benchmarks for AI-Driven C

Mon, 15 Jun 2026 08:10:00 -0400

Harbour BioMed and BioMap Jointly Initiate MegaStream TechBio: A Leading Global Drug Development Platform Joins Forces with Premier Life Science Foundation Models to Set New Benchmarks for AI-Driven C

Mon, 15 Jun 2026 08:10:00 -0400

Harbour BioMed and BioMap Jointly Initiate MegaStream TechBio: A Leading Global Drug Development Platform Joins Forces with Premier Life Science Foundation Models to Set New Benchmarks for AI-Driven C

Mon, 15 Jun 2026 08:10:00 -0400

Harbour BioMed wins $20.2 million patent case against Amgen

Sun, 14 Jun 2026 20:02:30 -0400

Harbour BioMed (HKEX: 02142) won a patent infringement lawsuit against Amgen Inc. and its subsidiary Teneobio Inc., with a Delaware jury awarding the company $20.2 million in damages on June 14.

The jury found that Amgen willfully infringed patents protecting Harbour BioMed's antibody discovery platform technology. The case was originally filed in 2021 by Harbour Antibodies, a member of the Harbour BioMed group.

After three hours of deliberation, the jury returned a unanimous verdict finding Amgen infringed the patent, the infringement was willful, the patent is valid, and Harbour BioMed is entitled to the full $20.2 million in damages requested.

The finding of

Harbour BioMed wins $20.2 million patent case against Amgen

Sun, 14 Jun 2026 20:02:30 -0400

Harbour BioMed (HKEX: 02142) won a patent infringement lawsuit against Amgen Inc. and its subsidiary Teneobio Inc., with a Delaware jury awarding the company $20.2 million in damages on June 14.

The finding of

Harbour BioMed wins $20.2 million patent case against Amgen

Sun, 14 Jun 2026 20:02:30 -0400

Harbour BioMed (HKEX: 02142) won a patent infringement lawsuit against Amgen Inc. and its subsidiary Teneobio Inc., with a Delaware jury awarding the company $20.2 million in damages on June 14.

The finding of

Harbour BioMed wins $20.2 million patent case against Amgen

Sun, 14 Jun 2026 20:02:30 -0400

Harbour BioMed (HKEX: 02142) won a patent infringement lawsuit against Amgen Inc. and its subsidiary Teneobio Inc., with a Delaware jury awarding the company $20.2 million in damages on June 14.

The finding of

Harbour BioMed wins $20.2 million patent case against Amgen

Sun, 14 Jun 2026 20:02:30 -0400

Harbour BioMed (HKEX: 02142) won a patent infringement lawsuit against Amgen Inc. and its subsidiary Teneobio Inc., with a Delaware jury awarding the company $20.2 million in damages on June 14.

The finding of

Harbour BioMed wins $20.2 million patent case against Amgen

Sun, 14 Jun 2026 20:02:30 -0400

Harbour BioMed (HKEX: 02142) won a patent infringement lawsuit against Amgen Inc. and its subsidiary Teneobio Inc., with a Delaware jury awarding the company $20.2 million in damages on June 14.

The finding of

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

Sun, 14 Jun 2026 20:01:00 -0400

The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery platform
Delaware jury finds infringement willful and patent valid, and awards full $20.2 million in damages; the findings of willful infringement also entitle the Company to petition the judge to treble the award, potentially increasing the award to up to $60.6 million
Harbour BioMed will continue to enforce its broader patent portfolio, with a focus on another patent with substantially greater financial implications—potentially representing up to ten times the damages awarded in this

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

Sun, 14 Jun 2026 20:01:00 -0400

The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery platform
Delaware jury finds infringement willful and patent valid, and awards full $20.2 million in damages; the findings of willful infringement also entitle the Company to petition the judge to treble the award, potentially increasing the award to up to $60.6 million
Harbour BioMed will continue to enforce its broader patent portfolio, with a focus on another patent with substantially greater financial implications—potentially representing up to ten times the damages awarded in this

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

Sun, 14 Jun 2026 20:01:00 -0400

The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery platform
Delaware jury finds infringement willful and patent valid, and awards full $20.2 million in damages; the findings of willful infringement also entitle the Company to petition the judge to treble the award, potentially increasing the award to up to $60.6 million
Harbour BioMed will continue to enforce its broader patent portfolio, with a focus on another patent with substantially greater financial implications—potentially representing up to ten times the damages awarded in this

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

Sun, 14 Jun 2026 20:01:00 -0400

The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery platform
Delaware jury finds infringement willful and patent valid, and awards full $20.2 million in damages; the findings of willful infringement also entitle the Company to petition the judge to treble the award, potentially increasing the award to up to $60.6 million
Harbour BioMed will continue to enforce its broader patent portfolio, with a focus on another patent with substantially greater financial implications—potentially representing up to ten times the damages awarded in this

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

Sun, 14 Jun 2026 20:01:00 -0400

The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery platform
Delaware jury finds infringement willful and patent valid, and awards full $20.2 million in damages; the findings of willful infringement also entitle the Company to petition the judge to treble the award, potentially increasing the award to up to $60.6 million
Harbour BioMed will continue to enforce its broader patent portfolio, with a focus on another patent with substantially greater financial implications—potentially representing up to ten times the damages awarded in this

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

Sun, 14 Jun 2026 20:01:00 -0400

The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery platform
Delaware jury finds infringement willful and patent valid, and awards full $20.2 million in damages; the findings of willful infringement also entitle the Company to petition the judge to treble the award, potentially increasing the award to up to $60.6 million
Harbour BioMed will continue to enforce its broader patent portfolio, with a focus on another patent with substantially greater financial implications—potentially representing up to ten times the damages awarded in this

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

Sun, 14 Jun 2026 20:01:00 -0400

The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery platform
Delaware jury finds infringement willful and patent valid, and awards full $20.2 million in damages; the findings of willful infringement also entitle the Company to petition the judge to treble the award, potentially increasing the award to up to $60.6 million
Harbour BioMed will continue to enforce its broader patent portfolio, with a focus on another patent with substantially greater financial implications—potentially representing up to ten times the damages awarded in this